Q3 Outcomes 2025 Stay At this time: Coforge, Persistent Methods, Pidilite shares leap, Adani Inexperienced Vitality, HPCL, Ultratech, Zee Leisure, Mphasis, Nippon to announce Q3 outcomes

Dr. Reddy’s Q3 outcomes dwell: Q3 FY25 web revenue prone to stay flat

Dr Reddy’s Laboratories’ web revenue is prone to stay little decrease or virtually flat at round ₹1360-65 crore within the third quarter of the present fiscal ended December 2024 in comparison with ₹1,378 crore posted within the corresponding quarter of earlier monetary yr.

The income, nevertheless, is projected to register as much as 10 per cent development to succeed in round ₹8,000 crore as in opposition to ₹7,248 crore within the year-ago interval by market estimates. The drug-maker is slated to launch Q3 numbers on January 23, 2025. The challenges for the Pharma main through the December quarter may very well be within the type of decrease gross sales of most cancers drug, Revlimid, and certain slowdown within the development within the US enterprise. 

Click on to know extra

Hindustan Unilever Q3 outcomes dwell: Shares fall 4%

Hindustan Unilever shares declined almost 4% to hit ₹2,253.85 following Q3 outcomes. Brokerages lower goal costs

UBS On HUL

• Impartial Name, Goal At `2,700/Sh
• Income Development Broadly In-line; Weak Product Combine Impacts UVG
• Quantity Led Development In Residence Care; Value Hike Impacts Private Care
• Anticipate Close to Time period Demand To Stay Comfortable
• Lower EPS Est For FY25-27 By 1-5% To Replicate Close to Time period Demand Weak point

CLSA On HUL

• Underperform Name, Goal Lower To `1,924/Sh
• Weak Development & Decrease Margin In Q3
• Three Of 4 Segments See UVG Decline; Minimalist Acquisition Introduced
• FY25-27 EPS Cuts Of 4-6%
• Margin To Weaken Particularly For Magnificence & Wellness As Development In Focus

GS On HUL

• Impartial Name, Tgt At `2,480/Sh
• Q3 Beneath Estimates On Quantity & EBITDA Development
• City Slowdown Has Worsened, Downtrading To Small Packs Underway
• Cleaning soap Volumes Decline Pushed By Excessive Value Will increase And Grammage Cuts
• EBITDA Margin Decrease YoY Regardless of Low Advert Spends
• Administration lowers close to time period outlook to moderating consumption atmosphere from secure atmosphere
• Acquired Minimalist at 6x EV/gross sales; the valuation appears honest given the acquisition is massive, worthwhile, synergistic and complementary.
• After many quarters, pricing turned constructive at 2%.

Nuvama on HUL

• Keep Purchase, TP 3225 (FROM 3395)
• Quantity development under expectations, general inline
• Given present RM inflation, we’re chopping FY25E/26E/27E EPS by 3%/5%/5%
• Investec on HUL
• Keep Maintain, TP 2643 (FROM 2654)
• No close to time period restoration on playing cards
• Close to-term development outcomes stay difficult for HUL
• sign weaker demand developments for the sector as a complete.
• HUL’s intent to take the inorganic route with the Minimalist acquisition (seemingly sub 1% of FY26E gross sales)
• Imagine seen triggers for bettering income development would be the drivers of earnings, valuation, and inventory value from present ranges

Adani Inexperienced Vitality, Adani Vitality Options Q3 outcomes dwell: Adani Vitality shares commerce flat 

Adani Vitality Options and Adani Inexperienced Vitality traded flat on the NSE at ₹799.55 and ₹1,036.50, respectively, forward of the Q3 outcomes right now. 

Pidilite Q3 outcomes dwell: Web revenue jumps 9%; Shares achieve

Pidilite shares zoomed 7.60% on the NSE to ₹2,964.20 as web revenue jumped 9% to ₹557 crore for the quarter ended December 2024 as in opposition to ₹511 crore within the corresponding quarter earlier yr. 

Persistent Methods Q3 outcomes, share value dwell

Persistent Methods inventory soared 7.96% on the NSE to ₹6,135.35, following sturdy Q3 numbers

Coforge Q3 outcomes dwell: Revenue, income rises

Coforge board has declared third interim dividend of Rs. 19. Coforge Inc., an entirely owned subsidiary of the Firm has agreed to enter right into a Inventory Buy Settlement with Xceltrait Inc. and its stockholders (“Inventory Buy Settlement”) to accumulate all the excellent shares of capital inventory of Xceltrait Inc. for combination buy consideration of roughly $ 17.85 million.

Firm recorded its consolidated income from operations for the quarter ended December 2024 at ₹3318.2 crore as in opposition to ₹2323.3 crore within the corresponding quarter earlier yr.

Inventory jumps 8.43% on the NSE to ₹8,922.10.

Q3 outcomes dwell: Shares that can see motion right now: January 23, 2025

Outcomes calendar: UltraTech Cement, Dr Reddy’s Laboratories, Hindustan Petroleum Company, Indus Towers, United Spirits, Adani Vitality Options, Adani Inexperienced Vitality, Amber Enterprises India, Capri International Capital, Cyient, Dai-ichi Karkaria, Greaves Cotton, Indian Vitality Change, KFin Applied sciences, Mankind Pharma, Mphasis, Nippon Life India Asset Administration, Senores Prescribed drugs, Sona BLW Precision Forgings, Spandana Sphoorty Monetary, Suryoday Small Finance Financial institution, Syngene Worldwide, Tata Teleservices, Tejas Networks, Thyrocare Applied sciences, Ujjivan Small Finance Financial institution, V2 Retail, and Zee Leisure Enterprises 

Learn extra